Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains. Subcutaneous tocilizumab, a targeted biotherapy, recently received marketing authorization for the treatment of GCA, but only demonstrated at yet that it can allow steroid dose sparing. The aim of this study is to assess the benefit of tocilizumab and IV steroids combination or IV steroids alone, in the treatment of AION due to GCA.
Epistemonikos ID: a5a5d26836bd23ad478f9e60aa4115d7e4d44a92
First added on: May 07, 2024